Ibogaine cardiac safety literature will constitute a recognized regulatory signal sufficient to require mandatory cardiac monitoring protocols in any new IND submission for ibogaine or close analogs, delaying direct ibogaine clinical development timelines materially into 2027.

Ibogaine's risk to heart rhythm is now documented clearly enough in published research that the FDA will treat it as an official safety signal. This means anyone wanting to run an ibogaine trial will face mandatory cardiac monitoring requirements, which will delay trial startup and add costs. FDA precedent shows they respond this way to cardiac risks in new brain drugs.

Five of seven simulation agents (fda_reviewer, neuropharmacologist, journalist, dea_officer, portfolio_manager) converged on this view. Dissenting agents (veteran_advocate, maps_researcher) argued compassionate-use pressure could override safety caution; this is historically rare for cardiac signals. The resolve criterion is operationalized as: at least one publicly documented FDA IND clinical hold or formal safety communication citing ibogaine QT/cardiac risk, issued before 2026-07-31. Confidence trimmed to 0.72 from 0.79: the 2026-07-31 resolve date is tight for a formal agency action; the underlying safety concern is well-founded but the specific artifact (public FDA action) may take longer to manifest.